@article{JTD24416,
author = {Dwight H. Owen and Gregory A. Otterson},
title = {Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 33},
year = {2018},
keywords = {},
abstract = {There are currently four immune checkpoint inhibitors (ICI) approved for the treatment of stage III or stage IV non-small cell lung cancer (NSCLC) in the United States, with dozens more in clinical development. Nivolumab and pembrolizumab are programmed death-1 (PD-1) antibodies, while atezolizumab and durvalumab are antibodies to programmed death ligand-1 (PD-L1) (1-5).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/24416}
}